Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine Hydrochloride in Rett Syndrome
NCT07503444Phase 3Recruiting
- Sponsor
- UCB
- Start
- Jul 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Rett syndrome (RTT) comparing fenfluramine hydrochloride with Placebo (2 arms). Primary endpoints: Rett Syndrome Behaviour Questionnaire Total Score at 14 weeks and Clinical Global Impression of Change Score at 14 weeks. Started Jul 2026; status: recruiting.
02
Drugs
fenfluramine
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT07503444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503444.